Estudos.

(1)

Estudos

(2)

LACTOBACILLUS GASSERI

Probiótico na perda de peso e redução da gordura

DESCRIÇÃO

Bactéria probiótica ácido lática que se origina no intestino humano.

MECANISMO DE AÇÃO

Estudos sugerem que o efeito antiobesidade do L. gasseri é atribuído a sua ação junto aos ácidos graxos, seja no aumento dos níveis de genes relacionados à sua oxidação como também na redução de genes referidos à síntese destes, além do aumento da expressão do GLUT4, principal transportador da glicose, com diminuição concomitante dos níveis de leptina plasmática e insulina. L. gasseri promove a redução nos níveis séricos de ácido graxos não esteroides pós-prandiais durante o jejum, apresentando possível contribuição para a redução do risco não só da obesidade como da Diabetes mellitus tipo 2.

INDICAÇÕES



 Otimizar e regular a microbiota intestinal;

 Redução da gordura visceral, subcutânea e abdominal; Controle ponderal;

 Resistência insulínica; Controle glicêmico;

 Intolerância à lactose.

DOSE USUAL

Recomendação de 6,9 x108_{à 6 x10}10_{UFC de Lactobacillus gasseri, até 3 vezes ao dia, antes das refeições.}

SUGESTÕES DE FÓRMULAS

PRINCIPAIS REFERÊNCIAS

KADOOKA, Y.; SATO, M.; OGAWA, A.; MIYOSHI, M.; UENISHI, H.; OGAWA, H.; IKUYAMA, K.; KAGOSHIMA, M.; TSUCHIDA, T. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. British Journal of Nutrition. v. 110, n. 9, p. 1696-703. Nov, 2013. Disponível em: < http://www.ncbi.nlm.nih.gov/pubmed/23614897>. Acesso em: 20 de Março de 2015, às 12:54. USMAN.; HOSONO A. Effect of Administration of Lactobacillus gasseri on Serum Lipids and Fecal Steroids in Hypercholesterolemic Rats. Journal of Dairy Science. V.83, nº 8,p.1705–1711. August 2000. Disponível em: http://www.sciencedirect.com/science/article/pii/S0022030200750399>. Acesso em: 30 de Março de 2015, às 14:19.

L. gasseri... 1x1010_UFC Chá verde (Camellia sinensis)…...500mg Base shake sem lactose qsp... 1 dose/sachê

Modo de uso: dissolver 1 sachê em 1 copo com

250mL de água ou suco, 1 a 2 vezes ao dia.

L. gasseri... 1x1010_UFC Frutooligossacarídeo (FOS)…... 6 g Sachê qsp... 1 sachê

Modo de uso: dissolver 2 sachês em 1 copo com

250mL água ou suco, 3 vezes ao dia, 30 min antes das principais refeições.

(3)

LACTOBACILLUS GASSERI

ESTUDOS CLÍNICOS

Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial

Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 % (95 % CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 % (95 % CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.

Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial

Background/Objectives:In spite of the much evidence for the beneficial effects of probiotics, their anti-obesity effects have not been well examined. We evaluated the effects of the probiotic Lactobacillus gasseri SBT2055 (LG2055) on abdominal adiposity, body weight and other body measures in adults with obese tendencies. Subjects/Methods: We conducted a multicenter, double-blind, randomized, placebo-controlled intervention trial. Subjects (n=87) with higher body mass index (BMI) (24.2–30.7 kg/m2_{) and abdominal visceral fat area (81.2–178.5 cm}2_{) were randomly assigned}

to receive either fermented milk (FM) containing LG2055 (active FM; n=43) or FM without LG2055 (control FM; n=44), and were asked to consume 200 g/day of FM for 12 weeks. Abdominal fat area was determined by computed tomography. Results:In the active FM group, abdominal visceral and subcutaneous fat areas significantly (P<0.01) decreased from baseline by an average of 4.6% (mean (confidence interval): −5.8 (−10.0, −1.7) cm2_{) and 3.3% (−7.4}

(−11.6, −3.1) cm2_{), respectively. Body weight and other measures also decreased significantly (P<0.001) as follows:}

body weight, 1.4% (−1.1 (−1.5, −0.7) kg); BMI, 1.5% (−0.4 (−0.5, −0.2) kg/m2_{); waist, 1.8% (−1.7 (−2.1, −1.4) cm); hip,}

1.5% (−1.5 (−1.8, −1.1) cm). In the control group, by contrast, none of these parameters decreased significantly. High-molecular weight adiponectin in serum increased significantly (P<0.01) in the active and control groups by 12.7% (0.17 (0.07, 0.26) μg/ml) and 13.6% (0.23 (0.07, 0.38) μg/ml), respectively.Conclusion: The probiotic LG2055 showed lowering effects on abdominal adiposity, body weight and other measures, suggesting its beneficial influence on metabolic disorders.

Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice.

Previously, we reported that Lactobacillus gasseri BNR17 (BNR17), a probiotic strain isolated from human breast milk, inhibited increases in body weight and adipocyte tissue weight in high-sucrose diet-fed Sprague-Dawley (SD) rats and reduced glucose levels in type 2 diabetes mice. In the current study, we conducted further experiments to extend these observations and elucidate the mechanism involved. C57BL/6J mice received a normal diet, high-sucrose diet or high-sucrose diet containing L. gasseri BNR17 (10(9) or 10(10) CFU) for 10 weeks. The administration of L. gasseri BNR17 significantly reduced the body weight and white adipose tissue weight regardless of the dose administered. In BNR17-fed groups, mRNA levels of fatty acid oxidation-related genes (ACO, CPT1, PPARα, PPARδ) were significantly higher and those of fatty acid synthesis-related genes (SREBP-1c, ACC) were lower compared to the high-sucrose-diet group. The expression of GLUT4, main glucose transporter-4, was elevated in BNR17-fed groups.

(4)

L. gasseri BNR17 also reduced the levels of leptin and insulin in serum. These results suggest that the anti-obesity

actions of L. gasseri BNR17 can be attributed to elevated expression of fatty acid oxidation-related genes and reduced levels of leptin. Additionally, data suggested the anti-diabetes activity of L. gasseri BNR17 may be to due elevated GLUT4 and reduced insulin levels.

REFERÊNCIAS

KADOOKA, Y.; SATO, M.; OGAWA, A.; MIYOSHI, M.; UENISHI, H.; OGAWA, H.; IKUYAMA, K.; KAGOSHIMA, M.; TSUCHIDA, T. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. British Journal of Nutrition. v. 110, n. 9, p. 1696-703. Nov, 2013. Disponível em: < http://www.ncbi.nlm.nih.gov/pubmed/23614897>. Acesso em: 20 de Março de 2015, às 12:54. Y KADOOKAY.;SATO M.; IMAIZUMIK.; OGAWAA.;IKUYAMA K.;AKAI Y.; OKANOM.; KAGOSHIMAM.;TSUCHIDA T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. European Journal of Clinical Nutrition. V. 64, p. 636–643, 2010. Dispomível em: < http://www.nature.com/ejcn/journal/v64/n6/full/ejcn201019a.html>. Acesso em: 23 de Março de 2015, às 09:44.

KANG, Ji-Hee et al. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One, v. 8, n. 1, p. e54617, 2013. Disponível em:< https://www.ncbi.nlm.nih.gov/pubmed/23382926>. Acesso em: 20 de Julho de 2017, às 15:36.

(5)